Journal ArticleOPEN ACCESS

Long-Term MC4R Agonist Treatment in POMC-Deficient Patients

  • Kühnen P
  • Clément K
New England Journal of Medicine (2022) 387(9) 852-854
DOI: 10.1056/nejmc2207442
24Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

Investigators report findings from the use of an all-oral regimen of bedaquiline, pretomanid, and linezolid in patients in the United States with multidrug-resistant or extensively drug-resistant tuberculosis.

Cite

CITATION STYLE

APA

Kühnen, P., & Clément, K. (2022). Long-Term MC4R Agonist Treatment in POMC-Deficient Patients. New England Journal of Medicine, 387(9), 852–854. https://doi.org/10.1056/nejmc2207442

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free